Kate Therapeutics
Sharif Tabebordbar is the Co-Founder and Chief Scientific Officer at Kate Therapeutics since October 2021. Previously, Sharif served as a Supervisor and Research Scientist at Broad Institute of MIT and Harvard from June 2017 to October 2021. Their experience also includes roles as a Scientist at Editas Medicine and as a Ph.D. Candidate at Harvard University. Sharif holds a Ph.D. in Biological and Biomedical Sciences from Harvard University, a Master of Science in Molecular Biotechnology from the University of Tehran, and a Bachelor of Science in Biotechnology from the University of Tehran.
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.